Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ratos AB ( ($SE:RATO.B) ) just unveiled an announcement.
Ratos has appointed Markus Granlund as the permanent CEO of TFS HealthScience, a global Contract Research Organization (CRO) specializing in clinical development services across various therapeutic areas. Granlund’s leadership is expected to enhance TFS’s operational efficiency and strategic positioning in the global CRO market, benefiting stakeholders through improved client value and patient outcomes.
The most recent analyst rating on ($SE:RATO.B) stock is a Buy with a SEK45.00 price target. To see the full list of analyst forecasts on Ratos AB stock, see the SE:RATO.B Stock Forecast page.
More about Ratos AB
Ratos is a Swedish publicly listed business group comprising 14 companies in Construction & Services, Industry, and Consumer sectors, primarily operating in the Nordic region. With headquarters in Stockholm, Ratos emphasizes core values such as Simplicity, Speed in Execution, and People-centric approaches, enabling its subsidiaries to thrive within a larger corporate framework.
Average Trading Volume: 564,800
Current Market Cap: SEK12.92B
See more data about RATO.B stock on TipRanks’ Stock Analysis page.